EP3580332A1 Mimetic Innate Immune Cell Generation from Pluripotent Stem Cells

The EPO has published patent application EP3580332A1 under the A1 publication kind, covering methods and kits for generating mimetic innate immune cells from pluripotent stem cells. The application names ZENG Jieming and WANG Shu as inventors and lists A61K 35/17 (cell preparations) and A61P 35/00 (antineoplastic agents) among its IPC classifications. The publication covers 27 designated EPC contracting states (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR).\n\nBiotechnology and pharmaceutical companies engaged in stem cell research, cell therapy development, or immunotherapy pipelines should review this publication to assess freedom-to-operate implications. Competitors working on innate immune cell generation or related oncology cell preparations may face new patent landscape constraints upon potential grant of the patent.